Bottneuro aims to become a leading provider of device based electric stimulation therapies for Alzheimer disease (AD). None of the pharmacological treatments available today slow or stop the progress of this fatal disease. Our NENI® neuromodulation platform technology enables a fast and reliable validation of novel stimulation protocols targeting glial cells which play an important role in the progress of AD. In Switzerland more than 150000 people are affected by AD causing yearly costs of about CHF 10 billion and are a huge burden for the family members as well. We plan to start with clinical trials in 2022 and expect to launch our first product in Switzerland beginning of 2025. We have a strong team with a broad expertise and several years of experience.
Company’s Keywords:
glial cells, alzheimers disease, electrical stimulation, digital therapies, diagnostics
<18
<
<2021
Your request has been submitted successfully.
Own or work here?